Arrowstreet Capital Limited Partnership Sells 112,182 Shares of Edwards Lifesciences Corporation $EW

Arrowstreet Capital Limited Partnership reduced its position in Edwards Lifesciences Corporation (NYSE:EW) by 42.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 153,874 shares of the medical research company’s stock after selling 112,182 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Edwards Lifesciences were worth $12,034,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Rosenberg Matthew Hamilton purchased a new position in Edwards Lifesciences in the second quarter worth about $28,000. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences during the first quarter valued at $26,000. NewSquare Capital LLC raised its holdings in shares of Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares in the last quarter. SouthState Corp purchased a new stake in Edwards Lifesciences during the first quarter worth $27,000. Finally, Atlantic Union Bankshares Corp bought a new position in Edwards Lifesciences in the second quarter worth about $40,000. 79.46% of the stock is currently owned by institutional investors.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. This trade represents a 24.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,816,265.10. The trade was a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 21,720 shares of company stock worth $1,814,660 over the last quarter. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Trading Down 1.3%

Shares of Edwards Lifesciences stock opened at $83.18 on Wednesday. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The company has a fifty day simple moving average of $81.19 and a 200-day simple moving average of $78.88. The stock has a market cap of $48.27 billion, a price-to-earnings ratio of 35.86, a PEG ratio of 3.79 and a beta of 0.97. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. Edwards Lifesciences’s revenue for the quarter was up 14.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on EW shares. Citigroup lifted their price objective on shares of Edwards Lifesciences from $95.00 to $96.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. National Bankshares set a $92.00 price target on shares of Edwards Lifesciences in a report on Friday, October 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Sanford C. Bernstein reissued a “market perform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Finally, Piper Sandler restated an “overweight” rating and set a $95.00 price target (up from $90.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $93.09.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.